The effectiveness of mono- and polychemotherapy as components of combined treatment of 142 cases of stage IV ovarian cancer was evaluated. Remission was 1.3 times more frequent (85.7%) and its mean duration (10.8 months) was longer in patients who had received polychemotherapy than in cases of monochemotherapy, the respective figures in the latter group being 66.7% and 5.7 months. A 3-year survival and life-span were identical in both study groups. Poly- and monochemotherapy are equally effective in treatment of primary ovarian cancer.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Synchronous clonally related anaplastic large cell lymphoma and malignant histiocytosis.
Diagn Pathol
January 2025
Laboratoire Hospitalier Universitaire de Bruxelles - Universitair Laboratorium Brussel, Université Libre de Bruxelles LHUB-ULB, Brussels, Belgium.
Background: Synchronous malignant histiocytoses are rare conditions that occur concurrently with another hematologic neoplasm. Most reported cases are associated with B-cell lymphoproliferative disorders, while associations with T-cell hemopathies are less common. These two diseases may share mutations and/or cytogenetic anomalies, which can lead to malignant proliferations.
View Article and Find Full Text PDFVirological Response to Lamivudine and Tenofovir Treatment in a Mono-infected Chronic Hepatitis B Patient with Potential Tenofovir Resistance: A Case Report.
J Clin Transl Hepatol
January 2025
Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Few cases of tenofovir resistance have been reported, and the appropriate treatment for such cases remains unclear. We aimed to share a case of a chronic hepatitis B mono-infected patient with potential tenofovir resistance who required combined lamivudine and tenofovir therapy to achieve adequate viral suppression. The patient's viral load (plasma) was monitored using the cobas® hepatitis B virus Test on the cobas® 6800 system.
View Article and Find Full Text PDFUse of isavuconazole in mucormycosis: a systematic review.
BMC Infect Dis
January 2025
Department of Microbiology Faculty of Medicine and Allied Sciences, Rajarata University of Sri Lanka, Saliyapura Sri Lanka, 50008, Sri Lanka.
Background: Mucormycosis is an opportunistic fungal infection which is associated with poor prognosis. Only a few antifungals are available in the arsenal against mucormycosis. The global guidelines for diagnosing and managing mucormycosis recommend high doses of liposomal amphotericin B (LAmB) as the first-line treatment.
View Article and Find Full Text PDFBee pollen peptides as potent tyrosinase inhibitors with anti-melanogenesis effects in murine b16f10 melanoma cells and zebrafish embryos.
Sci Rep
December 2024
Center of Excellence in Bioconversion and Bioseparation for Platform Chemical Production, Institute of Biotechnology and Genetic Engineering, Chulalongkorn University, 254 Phayathai Road, Pathumwan, Bangkok, 10330, Thailand.
One important functional food ingredient today, valued for its health properties and ability to prevent disease, is bee pollen, which comprises a combination of nectar, pollen from plants, and the secretions of bees. In this research, the tyrosinase (TYR) inhibiting abilities of the peptides derived from bee pollen protein hydrolysates are investigated. Various proteases were utilized to generate these peptides, followed by testing at different concentrations.
View Article and Find Full Text PDFAnticancer effects of PEP06 (TB01) in combination with Trifluridine/Tipiracil (TAS-102) in a xenograft model of human colorectal cancer.
J Cancer Res Clin Oncol
December 2024
Zhuhai Tengbai Pharmaceutical Co., Ltd, Zhuhai, 519031, China.
Background: Colorectal cancer (CRC) is the third most common cancer globally, with advanced stages presenting significant treatment challenges. Recently years, drug combination therapy has become a promising strategy for cancer treatment.
Objective: To evaluate the therapeutic efficacy of the combination of the anti-angiogenic drug PEP06 (TB01) and the cytotoxic drug Trifluridine/Tipiracil (TAS-102) in human CRC HCT-116 xenograft mouse model.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!